+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Blood Plasma Derivatives Market by Product Type, Application, End User, Source - Global Forecast 2025-2030- Product Image
Blood Plasma Derivatives Market by Product Type, Application, End User, Source - Global Forecast 2025-2030- Product Image
Sale

Blood Plasma Derivatives Market by Product Type, Application, End User, Source - Global Forecast 2025-2030

  • PDF Icon

    Report

  • 181 Pages
  • October 2024
  • Region: Global
  • 360iResearch™
  • ID: 6010980
UP TO OFF until Dec 31st 2024
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Blood Plasma Derivatives Market grew from USD 483.24 million in 2023 to USD 523.83 million in 2024. It is expected to continue growing at a CAGR of 9.65%, reaching USD 921.33 million by 2030.

Blood plasma derivatives comprise proteins collected and processed from human plasma, playing a crucial role in treating a myriad of medical conditions including immunodeficiencies, hemophilia, and autoimmune disorders. This sector is defined by its reliance on the voluntary donation of plasma, which, after being processed, helps in the development of medical therapies. The necessity of blood plasma derivatives stems from their ability to replace deficient or dysfunctional proteins in patients, thereby improving quality of life and managing symptoms of chronic conditions. Application areas are broad, ranging from hematology to neurology, and include treatments using immunoglobulins, albumin, clotting factors, and more. In terms of end-use, hospitals, clinics, research institutions, and pharmaceutical companies form the primary consumers of these derivatives due to their essential role in treating severe and often life-threatening diseases.

Market growth is driven by rising incidences of immune and bleeding disorders, an aging global population, and advancements in diagnostic technologies enhancing early detection rates. However, regulatory constraints, high production costs, and the ethical considerations surrounding plasma donation present formidable challenges. The COVID-19 pandemic also highlighted the dependency on blood plasma for producing convalescent plasma therapy, emphasizing the need for innovations in this area.

Opportunities for market players lie in expanding plasma collection networks, investing in recombinant product development to reduce reliance on human plasma, and entering emerging markets with rising healthcare investments. Innovation and research should focus on improving yield from plasma donations, developing synthetic alternatives to natural plasma proteins, and enhancing the safety and ease of plasma collection and processing.

One area ripe for innovation is the integration of AI and machine learning in plasma fractionation processes, which can optimize yields and reduce costs. Collaborations between biotech firms and academic researchers could accelerate the discovery of novel plasma-derived therapies. Overall, while the blood plasma derivatives market is poised for growth, strategic actions must be taken to navigate regulatory landscapes and ethical considerations, ensuring sustainable expansion and addressing healthcare needs.

Understanding Market Dynamics in the Blood Plasma Derivatives Market

The Blood Plasma Derivatives Market is rapidly evolving, shaped by dynamic supply and demand trends. These insights provide companies with actionable intelligence to drive investments, develop strategies, and seize emerging opportunities. A comprehensive understanding of market dynamics also helps organizations mitigate political, geographical, technical, social, and economic risks while offering a clearer view of consumer behavior and its effects on manufacturing costs and purchasing decisions.
  • Market Drivers
    • Increasing prevalence of chronic diseases driving demand for blood plasma derivatives globally
    • Rising investments in healthcare infrastructure and advanced plasma collection technologies
    • Government initiatives and favorable policies supporting blood plasma derivative research and development
    • Growing awareness and accessibility of plasma-derived therapies among patients and healthcare providers
  • Market Restraints
    • Logistical complexities in the collection, storage, and distribution of blood plasma for derivatives production
    • Ethical concerns and donor recruitment challenges affecting the supply chain of blood plasma derivatives
  • Market Opportunities
    • Expanding use of plasma-derived therapies in oncology and critical care
    • Technological advancements improving production efficiency of plasma derivatives
    • Government initiatives promoting the use of plasma products in public health emergencies
  • Market Challenges
    • High cost of blood plasma collection and processing limiting market expansion
    • Increasing competition from alternative therapies and biotechnology innovations in the plasma derivatives market

Exploring Porter’s Five Forces for the Blood Plasma Derivatives Market

Porter’s Five Forces framework further strengthens the insights of the Blood Plasma Derivatives Market, delivering a clear and effective methodology for understanding the competitive landscape. This tool enables companies to evaluate their current competitive standing and explore strategic repositioning by assessing businesses’ power dynamics and market positioning. It is also instrumental in determining the profitability of new ventures, helping companies leverage their strengths, address weaknesses, and avoid potential pitfalls.

Applying PESTLE Analysis to the Blood Plasma Derivatives Market

External macro-environmental factors deeply influence the performance of the Blood Plasma Derivatives Market, and the PESTLE analysis provides a comprehensive framework for understanding these influences. By examining Political, Economic, Social, Technological, Legal, and Environmental elements, this analysis offers organizations critical insights into potential opportunities and risks. It also helps businesses anticipate changes in regulations, consumer behavior, and economic trends, enabling them to make informed, forward-looking decisions.

Analyzing Market Share in the Blood Plasma Derivatives Market

The Blood Plasma Derivatives Market share analysis evaluates vendor performance. This analysis provides a clear view of each vendor’s standing in the competitive landscape by comparing key metrics such as revenue, customer base, and other critical factors. Additionally, it highlights market concentration, fragmentation, and trends in consolidation, empowering vendors to make strategic decisions that enhance their market position.

Evaluating Vendor Success with the FPNV Positioning Matrix in the Blood Plasma Derivatives Market

The Blood Plasma Derivatives Market FPNV Positioning Matrix is crucial in evaluating vendors based on business strategy and product satisfaction levels. By segmenting vendors into four quadrants - Forefront (F), Pathfinder (P), Niche (N), and Vital (V) - this matrix helps users make well-informed decisions that best align with their unique needs and objectives in the market.

Strategic Recommendations for Success in the Blood Plasma Derivatives Market

The Blood Plasma Derivatives Market strategic analysis is essential for organizations aiming to strengthen their position in the global market. A comprehensive review of resources, capabilities, and performance helps businesses identify opportunities for improvement and growth. This approach empowers companies to navigate challenges in the increasingly competitive landscape, ensuring they capitalize on new opportunities and align with long-term success.

Key Company Profiles

The report delves into recent significant developments in the Blood Plasma Derivatives Market, highlighting leading vendors and their innovative profiles. These include ADMA Biologics, ARTHREX GmbH, Bio Products Laboratory Ltd, Biotest AG, BPL Holdings, China Biologic Products Holdings, Inc., CSL Behring, Emergent BioSolutions, Grifols, Intas Pharmaceuticals, Kamada Ltd., Kedrion Biopharma, LFB Group, Octapharma, Prothya Biosolutions, RAAS Blood Products, Sanquin, Shanghai RAAS Blood Products Co., Ltd., Sichuan Yuanda Shuyang Pharmaceutical Co., Ltd., and Takeda Pharmaceutical Company Limited.

Market Segmentation & Coverage

This research report categorizes the Blood Plasma Derivatives Market to forecast the revenues and analyze trends in each of the following sub-markets:
  • Product Type
    • Albumin
    • Coagulation Factors
      • Factor IX
      • Factor VIII
      • Fibrinogen Concentrate
      • Prothrombin Complex Concentrate (PCC)
    • Immunoglobulins
      • Intravenous (IVIG)
      • Subcutaneous (SCIG)
  • Application
    • Diagnostics
    • Research
    • Therapeutic Use
      • Cardiology
      • Hemato-oncology
      • Immunology
      • Infectious Diseases
      • Neurology
      • Pulmonology
      • Trauma Emergencies
  • End User
    • Academic & Research Institutes
    • Blood Banks
    • Clinics
    • Diagnostic Laboratories
    • Hospitals
  • Source
    • Human Plasma
    • Non-Human Plasma
  • Region
    • Americas
      • Argentina
      • Brazil
      • Canada
      • Mexico
      • United States
        • California
        • Florida
        • Illinois
        • New York
        • Ohio
        • Pennsylvania
        • Texas
    • Asia-Pacific
      • Australia
      • China
      • India
      • Indonesia
      • Japan
      • Malaysia
      • Philippines
      • Singapore
      • South Korea
      • Taiwan
      • Thailand
      • Vietnam
    • Europe, Middle East & Africa
      • Denmark
      • Egypt
      • Finland
      • France
      • Germany
      • Israel
      • Italy
      • Netherlands
      • Nigeria
      • Norway
      • Poland
      • Qatar
      • Russia
      • Saudi Arabia
      • South Africa
      • Spain
      • Sweden
      • Switzerland
      • Turkey
      • United Arab Emirates
      • United Kingdom

The report provides a detailed overview of the market, exploring several key areas:

  1. Market Penetration: A thorough examination of the current market landscape, featuring comprehensive data from leading industry players and analyzing their reach and influence across the market.
  2. Market Development: The report identifies significant growth opportunities in emerging markets and assesses expansion potential within established segments, providing a roadmap for future development.
  3. Market Diversification: In-depth coverage of recent product launches, untapped geographic regions, significant industry developments, and strategic investments reshaping the market landscape.
  4. Competitive Assessment & Intelligence: A detailed analysis of the competitive landscape, covering market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, technological advancements, and innovations in manufacturing by key market players.
  5. Product Development & Innovation: Insight into groundbreaking technologies, R&D efforts, and product innovations that will drive the market in future.

Additionally, the report addresses key questions to assist stakeholders in making informed decisions:

  1. What is the current size of the market, and how is it expected to grow?
  2. Which products, segments, and regions present the most attractive investment opportunities?
  3. What are the prevailing technology trends and regulatory factors influencing the market?
  4. How do top vendors rank regarding market share and competitive positioning?
  5. What revenue sources and strategic opportunities guide vendors' market entry or exit decisions?

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
5. Market Insights
5.1. Market Dynamics
5.1.1. Drivers
5.1.1.1. Increasing prevalence of chronic diseases driving demand for blood plasma derivatives globally
5.1.1.2. Rising investments in healthcare infrastructure and advanced plasma collection technologies
5.1.1.3. Government initiatives and favorable policies supporting blood plasma derivative research and development
5.1.1.4. Growing awareness and accessibility of plasma-derived therapies among patients and healthcare providers
5.1.2. Restraints
5.1.2.1. Logistical complexities in the collection, storage, and distribution of blood plasma for derivatives production
5.1.2.2. Ethical concerns and donor recruitment challenges affecting the supply chain of blood plasma derivatives
5.1.3. Opportunities
5.1.3.1. Expanding use of plasma-derived therapies in oncology and critical care
5.1.3.2. Technological advancements improving production efficiency of plasma derivatives
5.1.3.3. Government initiatives promoting the use of plasma products in public health emergencies
5.1.4. Challenges
5.1.4.1. High cost of blood plasma collection and processing limiting market expansion
5.1.4.2. Increasing competition from alternative therapies and biotechnology innovations in the plasma derivatives market
5.2. Market Segmentation Analysis
5.3. Porter’s Five Forces Analysis
5.3.1. Threat of New Entrants
5.3.2. Threat of Substitutes
5.3.3. Bargaining Power of Customers
5.3.4. Bargaining Power of Suppliers
5.3.5. Industry Rivalry
5.4. PESTLE Analysis
5.4.1. Political
5.4.2. Economic
5.4.3. Social
5.4.4. Technological
5.4.5. Legal
5.4.6. Environmental
6. Blood Plasma Derivatives Market, by Product Type
6.1. Introduction
6.2. Albumin
6.3. Coagulation Factors
6.3.1. Factor IX
6.3.2. Factor VIII
6.3.3. Fibrinogen Concentrate
6.3.4. Prothrombin Complex Concentrate (PCC)
6.4. Immunoglobulins
6.4.1. Intravenous (IVIG)
6.4.2. Subcutaneous (SCIG)
7. Blood Plasma Derivatives Market, by Application
7.1. Introduction
7.2. Diagnostics
7.3. Research
7.4. Therapeutic Use
7.4.1. Cardiology
7.4.2. Hemato-oncology
7.4.3. Immunology
7.4.4. Infectious Diseases
7.4.5. Neurology
7.4.6. Pulmonology
7.4.7. Trauma Emergencies
8. Blood Plasma Derivatives Market, by End User
8.1. Introduction
8.2. Academic & Research Institutes
8.3. Blood Banks
8.4. Clinics
8.5. Diagnostic Laboratories
8.6. Hospitals
9. Blood Plasma Derivatives Market, by Source
9.1. Introduction
9.2. Human Plasma
9.3. Non-Human Plasma
10. Americas Blood Plasma Derivatives Market
10.1. Introduction
10.2. Argentina
10.3. Brazil
10.4. Canada
10.5. Mexico
10.6. United States
11. Asia-Pacific Blood Plasma Derivatives Market
11.1. Introduction
11.2. Australia
11.3. China
11.4. India
11.5. Indonesia
11.6. Japan
11.7. Malaysia
11.8. Philippines
11.9. Singapore
11.10. South Korea
11.11. Taiwan
11.12. Thailand
11.13. Vietnam
12. Europe, Middle East & Africa Blood Plasma Derivatives Market
12.1. Introduction
12.2. Denmark
12.3. Egypt
12.4. Finland
12.5. France
12.6. Germany
12.7. Israel
12.8. Italy
12.9. Netherlands
12.10. Nigeria
12.11. Norway
12.12. Poland
12.13. Qatar
12.14. Russia
12.15. Saudi Arabia
12.16. South Africa
12.17. Spain
12.18. Sweden
12.19. Switzerland
12.20. Turkey
12.21. United Arab Emirates
12.22. United Kingdom
13. Competitive Landscape
13.1. Market Share Analysis, 2023
13.2. FPNV Positioning Matrix, 2023
13.3. Competitive Scenario Analysis
13.4. Strategy Analysis & Recommendation
LIST OF FIGURES
FIGURE 1. BLOOD PLASMA DERIVATIVES MARKET RESEARCH PROCESS
FIGURE 2. BLOOD PLASMA DERIVATIVES MARKET SIZE, 2023 VS 2030
FIGURE 3. GLOBAL BLOOD PLASMA DERIVATIVES MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 4. GLOBAL BLOOD PLASMA DERIVATIVES MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 5. GLOBAL BLOOD PLASMA DERIVATIVES MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 6. GLOBAL BLOOD PLASMA DERIVATIVES MARKET SIZE, BY PRODUCT TYPE, 2023 VS 2030 (%)
FIGURE 7. GLOBAL BLOOD PLASMA DERIVATIVES MARKET SIZE, BY PRODUCT TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 8. GLOBAL BLOOD PLASMA DERIVATIVES MARKET SIZE, BY APPLICATION, 2023 VS 2030 (%)
FIGURE 9. GLOBAL BLOOD PLASMA DERIVATIVES MARKET SIZE, BY APPLICATION, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 10. GLOBAL BLOOD PLASMA DERIVATIVES MARKET SIZE, BY END USER, 2023 VS 2030 (%)
FIGURE 11. GLOBAL BLOOD PLASMA DERIVATIVES MARKET SIZE, BY END USER, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 12. GLOBAL BLOOD PLASMA DERIVATIVES MARKET SIZE, BY SOURCE, 2023 VS 2030 (%)
FIGURE 13. GLOBAL BLOOD PLASMA DERIVATIVES MARKET SIZE, BY SOURCE, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 14. AMERICAS BLOOD PLASMA DERIVATIVES MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 15. AMERICAS BLOOD PLASMA DERIVATIVES MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 16. UNITED STATES BLOOD PLASMA DERIVATIVES MARKET SIZE, BY STATE, 2023 VS 2030 (%)
FIGURE 17. UNITED STATES BLOOD PLASMA DERIVATIVES MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 18. ASIA-PACIFIC BLOOD PLASMA DERIVATIVES MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 19. ASIA-PACIFIC BLOOD PLASMA DERIVATIVES MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 20. EUROPE, MIDDLE EAST & AFRICA BLOOD PLASMA DERIVATIVES MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 21. EUROPE, MIDDLE EAST & AFRICA BLOOD PLASMA DERIVATIVES MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 22. BLOOD PLASMA DERIVATIVES MARKET SHARE, BY KEY PLAYER, 2023
FIGURE 23. BLOOD PLASMA DERIVATIVES MARKET, FPNV POSITIONING MATRIX, 2023
LIST OF TABLES
TABLE 1. BLOOD PLASMA DERIVATIVES MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
TABLE 3. GLOBAL BLOOD PLASMA DERIVATIVES MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL BLOOD PLASMA DERIVATIVES MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. GLOBAL BLOOD PLASMA DERIVATIVES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 6. BLOOD PLASMA DERIVATIVES MARKET DYNAMICS
TABLE 7. GLOBAL BLOOD PLASMA DERIVATIVES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 8. GLOBAL BLOOD PLASMA DERIVATIVES MARKET SIZE, BY ALBUMIN, BY REGION, 2018-2030 (USD MILLION)
TABLE 9. GLOBAL BLOOD PLASMA DERIVATIVES MARKET SIZE, BY COAGULATION FACTORS, BY REGION, 2018-2030 (USD MILLION)
TABLE 10. GLOBAL BLOOD PLASMA DERIVATIVES MARKET SIZE, BY FACTOR IX, BY REGION, 2018-2030 (USD MILLION)
TABLE 11. GLOBAL BLOOD PLASMA DERIVATIVES MARKET SIZE, BY FACTOR VIII, BY REGION, 2018-2030 (USD MILLION)
TABLE 12. GLOBAL BLOOD PLASMA DERIVATIVES MARKET SIZE, BY FIBRINOGEN CONCENTRATE, BY REGION, 2018-2030 (USD MILLION)
TABLE 13. GLOBAL BLOOD PLASMA DERIVATIVES MARKET SIZE, BY PROTHROMBIN COMPLEX CONCENTRATE (PCC), BY REGION, 2018-2030 (USD MILLION)
TABLE 14. GLOBAL BLOOD PLASMA DERIVATIVES MARKET SIZE, BY COAGULATION FACTORS, 2018-2030 (USD MILLION)
TABLE 15. GLOBAL BLOOD PLASMA DERIVATIVES MARKET SIZE, BY IMMUNOGLOBULINS, BY REGION, 2018-2030 (USD MILLION)
TABLE 16. GLOBAL BLOOD PLASMA DERIVATIVES MARKET SIZE, BY INTRAVENOUS (IVIG), BY REGION, 2018-2030 (USD MILLION)
TABLE 17. GLOBAL BLOOD PLASMA DERIVATIVES MARKET SIZE, BY SUBCUTANEOUS (SCIG), BY REGION, 2018-2030 (USD MILLION)
TABLE 18. GLOBAL BLOOD PLASMA DERIVATIVES MARKET SIZE, BY IMMUNOGLOBULINS, 2018-2030 (USD MILLION)
TABLE 19. GLOBAL BLOOD PLASMA DERIVATIVES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 20. GLOBAL BLOOD PLASMA DERIVATIVES MARKET SIZE, BY DIAGNOSTICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 21. GLOBAL BLOOD PLASMA DERIVATIVES MARKET SIZE, BY RESEARCH, BY REGION, 2018-2030 (USD MILLION)
TABLE 22. GLOBAL BLOOD PLASMA DERIVATIVES MARKET SIZE, BY THERAPEUTIC USE, BY REGION, 2018-2030 (USD MILLION)
TABLE 23. GLOBAL BLOOD PLASMA DERIVATIVES MARKET SIZE, BY CARDIOLOGY, BY REGION, 2018-2030 (USD MILLION)
TABLE 24. GLOBAL BLOOD PLASMA DERIVATIVES MARKET SIZE, BY HEMATO-ONCOLOGY, BY REGION, 2018-2030 (USD MILLION)
TABLE 25. GLOBAL BLOOD PLASMA DERIVATIVES MARKET SIZE, BY IMMUNOLOGY, BY REGION, 2018-2030 (USD MILLION)
TABLE 26. GLOBAL BLOOD PLASMA DERIVATIVES MARKET SIZE, BY INFECTIOUS DISEASES, BY REGION, 2018-2030 (USD MILLION)
TABLE 27. GLOBAL BLOOD PLASMA DERIVATIVES MARKET SIZE, BY NEUROLOGY, BY REGION, 2018-2030 (USD MILLION)
TABLE 28. GLOBAL BLOOD PLASMA DERIVATIVES MARKET SIZE, BY PULMONOLOGY, BY REGION, 2018-2030 (USD MILLION)
TABLE 29. GLOBAL BLOOD PLASMA DERIVATIVES MARKET SIZE, BY TRAUMA EMERGENCIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 30. GLOBAL BLOOD PLASMA DERIVATIVES MARKET SIZE, BY THERAPEUTIC USE, 2018-2030 (USD MILLION)
TABLE 31. GLOBAL BLOOD PLASMA DERIVATIVES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 32. GLOBAL BLOOD PLASMA DERIVATIVES MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, BY REGION, 2018-2030 (USD MILLION)
TABLE 33. GLOBAL BLOOD PLASMA DERIVATIVES MARKET SIZE, BY BLOOD BANKS, BY REGION, 2018-2030 (USD MILLION)
TABLE 34. GLOBAL BLOOD PLASMA DERIVATIVES MARKET SIZE, BY CLINICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 35. GLOBAL BLOOD PLASMA DERIVATIVES MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 36. GLOBAL BLOOD PLASMA DERIVATIVES MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
TABLE 37. GLOBAL BLOOD PLASMA DERIVATIVES MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
TABLE 38. GLOBAL BLOOD PLASMA DERIVATIVES MARKET SIZE, BY HUMAN PLASMA, BY REGION, 2018-2030 (USD MILLION)
TABLE 39. GLOBAL BLOOD PLASMA DERIVATIVES MARKET SIZE, BY NON-HUMAN PLASMA, BY REGION, 2018-2030 (USD MILLION)
TABLE 40. AMERICAS BLOOD PLASMA DERIVATIVES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 41. AMERICAS BLOOD PLASMA DERIVATIVES MARKET SIZE, BY COAGULATION FACTORS, 2018-2030 (USD MILLION)
TABLE 42. AMERICAS BLOOD PLASMA DERIVATIVES MARKET SIZE, BY IMMUNOGLOBULINS, 2018-2030 (USD MILLION)
TABLE 43. AMERICAS BLOOD PLASMA DERIVATIVES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 44. AMERICAS BLOOD PLASMA DERIVATIVES MARKET SIZE, BY THERAPEUTIC USE, 2018-2030 (USD MILLION)
TABLE 45. AMERICAS BLOOD PLASMA DERIVATIVES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 46. AMERICAS BLOOD PLASMA DERIVATIVES MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
TABLE 47. AMERICAS BLOOD PLASMA DERIVATIVES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 48. ARGENTINA BLOOD PLASMA DERIVATIVES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 49. ARGENTINA BLOOD PLASMA DERIVATIVES MARKET SIZE, BY COAGULATION FACTORS, 2018-2030 (USD MILLION)
TABLE 50. ARGENTINA BLOOD PLASMA DERIVATIVES MARKET SIZE, BY IMMUNOGLOBULINS, 2018-2030 (USD MILLION)
TABLE 51. ARGENTINA BLOOD PLASMA DERIVATIVES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 52. ARGENTINA BLOOD PLASMA DERIVATIVES MARKET SIZE, BY THERAPEUTIC USE, 2018-2030 (USD MILLION)
TABLE 53. ARGENTINA BLOOD PLASMA DERIVATIVES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 54. ARGENTINA BLOOD PLASMA DERIVATIVES MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
TABLE 55. BRAZIL BLOOD PLASMA DERIVATIVES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 56. BRAZIL BLOOD PLASMA DERIVATIVES MARKET SIZE, BY COAGULATION FACTORS, 2018-2030 (USD MILLION)
TABLE 57. BRAZIL BLOOD PLASMA DERIVATIVES MARKET SIZE, BY IMMUNOGLOBULINS, 2018-2030 (USD MILLION)
TABLE 58. BRAZIL BLOOD PLASMA DERIVATIVES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 59. BRAZIL BLOOD PLASMA DERIVATIVES MARKET SIZE, BY THERAPEUTIC USE, 2018-2030 (USD MILLION)
TABLE 60. BRAZIL BLOOD PLASMA DERIVATIVES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 61. BRAZIL BLOOD PLASMA DERIVATIVES MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
TABLE 62. CANADA BLOOD PLASMA DERIVATIVES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 63. CANADA BLOOD PLASMA DERIVATIVES MARKET SIZE, BY COAGULATION FACTORS, 2018-2030 (USD MILLION)
TABLE 64. CANADA BLOOD PLASMA DERIVATIVES MARKET SIZE, BY IMMUNOGLOBULINS, 2018-2030 (USD MILLION)
TABLE 65. CANADA BLOOD PLASMA DERIVATIVES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 66. CANADA BLOOD PLASMA DERIVATIVES MARKET SIZE, BY THERAPEUTIC USE, 2018-2030 (USD MILLION)
TABLE 67. CANADA BLOOD PLASMA DERIVATIVES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 68. CANADA BLOOD PLASMA DERIVATIVES MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
TABLE 69. MEXICO BLOOD PLASMA DERIVATIVES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 70. MEXICO BLOOD PLASMA DERIVATIVES MARKET SIZE, BY COAGULATION FACTORS, 2018-2030 (USD MILLION)
TABLE 71. MEXICO BLOOD PLASMA DERIVATIVES MARKET SIZE, BY IMMUNOGLOBULINS, 2018-2030 (USD MILLION)
TABLE 72. MEXICO BLOOD PLASMA DERIVATIVES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 73. MEXICO BLOOD PLASMA DERIVATIVES MARKET SIZE, BY THERAPEUTIC USE, 2018-2030 (USD MILLION)
TABLE 74. MEXICO BLOOD PLASMA DERIVATIVES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 75. MEXICO BLOOD PLASMA DERIVATIVES MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
TABLE 76. UNITED STATES BLOOD PLASMA DERIVATIVES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 77. UNITED STATES BLOOD PLASMA DERIVATIVES MARKET SIZE, BY COAGULATION FACTORS, 2018-2030 (USD MILLION)
TABLE 78. UNITED STATES BLOOD PLASMA DERIVATIVES MARKET SIZE, BY IMMUNOGLOBULINS, 2018-2030 (USD MILLION)
TABLE 79. UNITED STATES BLOOD PLASMA DERIVATIVES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 80. UNITED STATES BLOOD PLASMA DERIVATIVES MARKET SIZE, BY THERAPEUTIC USE, 2018-2030 (USD MILLION)
TABLE 81. UNITED STATES BLOOD PLASMA DERIVATIVES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 82. UNITED STATES BLOOD PLASMA DERIVATIVES MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
TABLE 83. UNITED STATES BLOOD PLASMA DERIVATIVES MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 84. ASIA-PACIFIC BLOOD PLASMA DERIVATIVES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 85. ASIA-PACIFIC BLOOD PLASMA DERIVATIVES MARKET SIZE, BY COAGULATION FACTORS, 2018-2030 (USD MILLION)
TABLE 86. ASIA-PACIFIC BLOOD PLASMA DERIVATIVES MARKET SIZE, BY IMMUNOGLOBULINS, 2018-2030 (USD MILLION)
TABLE 87. ASIA-PACIFIC BLOOD PLASMA DERIVATIVES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 88. ASIA-PACIFIC BLOOD PLASMA DERIVATIVES MARKET SIZE, BY THERAPEUTIC USE, 2018-2030 (USD MILLION)
TABLE 89. ASIA-PACIFIC BLOOD PLASMA DERIVATIVES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 90. ASIA-PACIFIC BLOOD PLASMA DERIVATIVES MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
TABLE 91. ASIA-PACIFIC BLOOD PLASMA DERIVATIVES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 92. AUSTRALIA BLOOD PLASMA DERIVATIVES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 93. AUSTRALIA BLOOD PLASMA DERIVATIVES MARKET SIZE, BY COAGULATION FACTORS, 2018-2030 (USD MILLION)
TABLE 94. AUSTRALIA BLOOD PLASMA DERIVATIVES MARKET SIZE, BY IMMUNOGLOBULINS, 2018-2030 (USD MILLION)
TABLE 95. AUSTRALIA BLOOD PLASMA DERIVATIVES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 96. AUSTRALIA BLOOD PLASMA DERIVATIVES MARKET SIZE, BY THERAPEUTIC USE, 2018-2030 (USD MILLION)
TABLE 97. AUSTRALIA BLOOD PLASMA DERIVATIVES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 98. AUSTRALIA BLOOD PLASMA DERIVATIVES MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
TABLE 99. CHINA BLOOD PLASMA DERIVATIVES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 100. CHINA BLOOD PLASMA DERIVATIVES MARKET SIZE, BY COAGULATION FACTORS, 2018-2030 (USD MILLION)
TABLE 101. CHINA BLOOD PLASMA DERIVATIVES MARKET SIZE, BY IMMUNOGLOBULINS, 2018-2030 (USD MILLION)
TABLE 102. CHINA BLOOD PLASMA DERIVATIVES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 103. CHINA BLOOD PLASMA DERIVATIVES MARKET SIZE, BY THERAPEUTIC USE, 2018-2030 (USD MILLION)
TABLE 104. CHINA BLOOD PLASMA DERIVATIVES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 105. CHINA BLOOD PLASMA DERIVATIVES MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
TABLE 106. INDIA BLOOD PLASMA DERIVATIVES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 107. INDIA BLOOD PLASMA DERIVATIVES MARKET SIZE, BY COAGULATION FACTORS, 2018-2030 (USD MILLION)
TABLE 108. INDIA BLOOD PLASMA DERIVATIVES MARKET SIZE, BY IMMUNOGLOBULINS, 2018-2030 (USD MILLION)
TABLE 109. INDIA BLOOD PLASMA DERIVATIVES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 110. INDIA BLOOD PLASMA DERIVATIVES MARKET SIZE, BY THERAPEUTIC USE, 2018-2030 (USD MILLION)
TABLE 111. INDIA BLOOD PLASMA DERIVATIVES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 112. INDIA BLOOD PLASMA DERIVATIVES MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
TABLE 113. INDONESIA BLOOD PLASMA DERIVATIVES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 114. INDONESIA BLOOD PLASMA DERIVATIVES MARKET SIZE, BY COAGULATION FACTORS, 2018-2030 (USD MILLION)
TABLE 115. INDONESIA BLOOD PLASMA DERIVATIVES MARKET SIZE, BY IMMUNOGLOBULINS, 2018-2030 (USD MILLION)
TABLE 116. INDONESIA BLOOD PLASMA DERIVATIVES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 117. INDONESIA BLOOD PLASMA DERIVATIVES MARKET SIZE, BY THERAPEUTIC USE, 2018-2030 (USD MILLION)
TABLE 118. INDONESIA BLOOD PLASMA DERIVATIVES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 119. INDONESIA BLOOD PLASMA DERIVATIVES MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
TABLE 120. JAPAN BLOOD PLASMA DERIVATIVES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 121. JAPAN BLOOD PLASMA DERIVATIVES MARKET SIZE, BY COAGULATION FACTORS, 2018-2030 (USD MILLION)
TABLE 122. JAPAN BLOOD PLASMA DERIVATIVES MARKET SIZE, BY IMMUNOGLOBULINS, 2018-2030 (USD MILLION)
TABLE 123. JAPAN BLOOD PLASMA DERIVATIVES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 124. JAPAN BLOOD PLASMA DERIVATIVES MARKET SIZE, BY THERAPEUTIC USE, 2018-2030 (USD MILLION)
TABLE 125. JAPAN BLOOD PLASMA DERIVATIVES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 126. JAPAN BLOOD PLASMA DERIVATIVES MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
TABLE 127. MALAYSIA BLOOD PLASMA DERIVATIVES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 128. MALAYSIA BLOOD PLASMA DERIVATIVES MARKET SIZE, BY COAGULATION FACTORS, 2018-2030 (USD MILLION)
TABLE 129. MALAYSIA BLOOD PLASMA DERIVATIVES MARKET SIZE, BY IMMUNOGLOBULINS, 2018-2030 (USD MILLION)
TABLE 130. MALAYSIA BLOOD PLASMA DERIVATIVES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 131. MALAYSIA BLOOD PLASMA DERIVATIVES MARKET SIZE, BY THERAPEUTIC USE, 2018-2030 (USD MILLION)
TABLE 132. MALAYSIA BLOOD PLASMA DERIVATIVES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 133. MALAYSIA BLOOD PLASMA DERIVATIVES MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
TABLE 134. PHILIPPINES BLOOD PLASMA DERIVATIVES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 135. PHILIPPINES BLOOD PLASMA DERIVATIVES MARKET SIZE, BY COAGULATION FACTORS, 2018-2030 (USD MILLION)
TABLE 136. PHILIPPINES BLOOD PLASMA DERIVATIVES MARKET SIZE, BY IMMUNOGLOBULINS, 2018-2030 (USD MILLION)
TABLE 137. PHILIPPINES BLOOD PLASMA DERIVATIVES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 138. PHILIPPINES BLOOD PLASMA DERIVATIVES MARKET SIZE, BY THERAPEUTIC USE, 2018-2030 (USD MILLION)
TABLE 139. PHILIPPINES BLOOD PLASMA DERIVATIVES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 140. PHILIPPINES BLOOD PLASMA DERIVATIVES MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
TABLE 141. SINGAPORE BLOOD PLASMA DERIVATIVES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 142. SINGAPORE BLOOD PLASMA DERIVATIVES MARKET SIZE, BY COAGULATION FACTORS, 2018-2030 (USD MILLION)
TABLE 143. SINGAPORE BLOOD PLASMA DERIVATIVES MARKET SIZE, BY IMMUNOGLOBULINS, 2018-2030 (USD MILLION)
TABLE 144. SINGAPORE BLOOD PLASMA DERIVATIVES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 145. SINGAPORE BLOOD PLASMA DERIVATIVES MARKET SIZE, BY THERAPEUTIC USE, 2018-2030 (USD MILLION)
TABLE 146. SINGAPORE BLOOD PLASMA DERIVATIVES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 147. SINGAPORE BLOOD PLASMA DERIVATIVES MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
TABLE 148. SOUTH KOREA BLOOD PLASMA DERIVATIVES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 149. SOUTH KOREA BLOOD PLASMA DERIVATIVES MARKET SIZE, BY COAGULATION FACTORS, 2018-2030 (USD MILLION)
TABLE 150. SOUTH KOREA BLOOD PLASMA DERIVATIVES MARKET SIZE, BY IMMUNOGLOBULINS, 2018-2030 (USD MILLION)
TABLE 151. SOUTH KOREA BLOOD PLASMA DERIVATIVES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 152. SOUTH KOREA BLOOD PLASMA DERIVATIVES MARKET SIZE, BY THERAPEUTIC USE, 2018-2030 (USD MILLION)
TABLE 153. SOUTH KOREA BLOOD PLASMA DERIVATIVES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 154. SOUTH KOREA BLOOD PLASMA DERIVATIVES MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
TABLE 155. TAIWAN BLOOD PLASMA DERIVATIVES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 156. TAIWAN BLOOD PLASMA DERIVATIVES MARKET SIZE, BY COAGULATION FACTORS, 2018-2030 (USD MILLION)
TABLE 157. TAIWAN BLOOD PLASMA DERIVATIVES MARKET SIZE, BY IMMUNOGLOBULINS, 2018-2030 (USD MILLION)
TABLE 158. TAIWAN BLOOD PLASMA DERIVATIVES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 159. TAIWAN BLOOD PLASMA DERIVATIVES MARKET SIZE, BY THERAPEUTIC USE, 2018-2030 (USD MILLION)
TABLE 160. TAIWAN BLOOD PLASMA DERIVATIVES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 161. TAIWAN BLOOD PLASMA DERIVATIVES MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
TABLE 162. THAILAND BLOOD PLASMA DERIVATIVES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 163. THAILAND BLOOD PLASMA DERIVATIVES MARKET SIZE, BY COAGULATION FACTORS, 2018-2030 (USD MILLION)
TABLE 164. THAILAND BLOOD PLASMA DERIVATIVES MARKET SIZE, BY IMMUNOGLOBULINS, 2018-2030 (USD MILLION)
TABLE 165. THAILAND BLOOD PLASMA DERIVATIVES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 166. THAILAND BLOOD PLASMA DERIVATIVES MARKET SIZE, BY THERAPEUTIC USE, 2018-2030 (USD MILLION)
TABLE 167. THAILAND BLOOD PLASMA DERIVATIVES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 168. THAILAND BLOOD PLASMA DERIVATIVES MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
TABLE 169. VIETNAM BLOOD PLASMA DERIVATIVES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 170. VIETNAM BLOOD PLASMA DERIVATIVES MARKET SIZE, BY COAGULATION FACTORS, 2018-2030 (USD MILLION)
TABLE 171. VIETNAM BLOOD PLASMA DERIVATIVES MARKET SIZE, BY IMMUNOGLOBULINS, 2018-2030 (USD MILLION)
TABLE 172. VIETNAM BLOOD PLASMA DERIVATIVES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 173. VIETNAM BLOOD PLASMA DERIVATIVES MARKET SIZE, BY THERAPEUTIC USE, 2018-2030 (USD MILLION)
TABLE 174. VIETNAM BLOOD PLASMA DERIVATIVES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 175. VIETNAM BLOOD PLASMA DERIVATIVES MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
TABLE 176. EUROPE, MIDDLE EAST & AFRICA BLOOD PLASMA DERIVATIVES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 177. EUROPE, MIDDLE EAST & AFRICA BLOOD PLASMA DERIVATIVES MARKET SIZE, BY COAGULATION FACTORS, 2018-2030 (USD MILLION)
TABLE 178. EUROPE, MIDDLE EAST & AFRICA BLOOD PLASMA DERIVATIVES MARKET SIZE, BY IMMUNOGLOBULINS, 2018-2030 (USD MILLION)
TABLE 179. EUROPE, MIDDLE EAST & AFRICA BLOOD PLASMA DERIVATIVES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 180. EUROPE, MIDDLE EAST & AFRICA BLOOD PLASMA DERIVATIVES MARKET SIZE, BY THERAPEUTIC USE, 2018-2030 (USD MILLION)
TABLE 181. EUROPE, MIDDLE EAST & AFRICA BLOOD PLASMA DERIVATIVES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 182. EUROPE, MIDDLE EAST & AFRICA BLOOD PLASMA DERIVATIVES MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
TABLE 183. EUROPE, MIDDLE EAST & AFRICA BLOOD PLASMA DERIVATIVES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 184. DENMARK BLOOD PLASMA DERIVATIVES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 185. DENMARK BLOOD PLASMA DERIVATIVES MARKET SIZE, BY COAGULATION FACTORS, 2018-2030 (USD MILLION)
TABLE 186. DENMARK BLOOD PLASMA DERIVATIVES MARKET SIZE, BY IMMUNOGLOBULINS, 2018-2030 (USD MILLION)
TABLE 187. DENMARK BLOOD PLASMA DERIVATIVES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 188. DENMARK BLOOD PLASMA DERIVATIVES MARKET SIZE, BY THERAPEUTIC USE, 2018-2030 (USD MILLION)
TABLE 189. DENMARK BLOOD PLASMA DERIVATIVES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 190. DENMARK BLOOD PLASMA DERIVATIVES MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
TABLE 191. EGYPT BLOOD PLASMA DERIVATIVES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 192. EGYPT BLOOD PLASMA DERIVATIVES MARKET SIZE, BY COAGULATION FACTORS, 2018-2030 (USD MILLION)
TABLE 193. EGYPT BLOOD PLASMA DERIVATIVES MARKET SIZE, BY IMMUNOGLOBULINS, 2018-2030 (USD MILLION)
TABLE 194. EGYPT BLOOD PLASMA DERIVATIVES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 195. EGYPT BLOOD PLASMA DERIVATIVES MARKET SIZE, BY THERAPEUTIC USE, 2018-2030 (USD MILLION)
TABLE 196. EGYPT BLOOD PLASMA DERIVATIVES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 197. EGYPT BLOOD PLASMA DERIVATIVES MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
TABLE 198. FINLAND BLOOD PLASMA DERIVATIVES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 199. FINLAND BLOOD PLASMA DERIVATIVES MARKET SIZE, BY COAGULATION FACTORS, 2018-2030 (USD MILLION)
TABLE 200. FINLAND BLOOD PLASMA DERIVATIVES MARKET SIZE, BY IMMUNOGLOBULINS, 2018-2030 (USD MILLION)
TABLE 201. FINLAND BLOOD PLASMA DERIVATIVES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 202. FINLAND BLOOD PLASMA DERIVATIVES MARKET SIZE, BY THERAPEUTIC USE, 2018-2030 (USD MILLION)
TABLE 203. FINLAND BLOOD PLASMA DERIVATIVES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 204. FINLAND BLOOD PLASMA DERIVATIVES MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
TABLE 205. FRANCE BLOOD PLASMA DERIVATIVES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 206. FRANCE BLOOD PLASMA DERIVATIVES MARKET SIZE, BY COAGULATION FACTORS, 2018-2030 (USD MILLION)
TABLE 207. FRANCE BLOOD PLASMA DERIVATIVES MARKET SIZE, BY IMMUNOGLOBULINS, 2018-2030 (USD MILLION)
TABLE 208. FRANCE BLOOD PLASMA DERIVATIVES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 209. FRANCE BLOOD PLASMA DERIVATIVES MARKET SIZE, BY THERAPEUTIC USE, 2018-2030 (USD MILLION)
TABLE 210. FRANCE BLOOD PLASMA DERIVATIVES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 211. FRANCE BLOOD PLASMA DERIVATIVES MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
TABLE 212. GERMANY BLOOD PLASMA DERIVATIVES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 213. GERMANY BLOOD PLASMA DERIVATIVES MARKET SIZE, BY COAGULATION FACTORS, 2018-2030 (USD MILLION)
TABLE 214. GERMANY BLOOD PLASMA DERIVATIVES MARKET SIZE, BY IMMUNOGLOBULINS, 2018-2030 (USD MILLION)
TABLE 215. GERMANY BLOOD PLASMA DERIVATIVES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 216. GERMANY BLOOD PLASMA DERIVATIVES MARKET SIZE, BY THERAPEUTIC USE, 2018-2030 (USD MILLION)
TABLE 217. GERMANY BLOOD PLASMA DERIVATIVES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 218. GERMANY BLOOD PLASMA DERIVATIVES MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
TABLE 219. ISRAEL BLOOD PLASMA DERIVATIVES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 220. ISRAEL BLOOD PLASMA DERIVATIVES MARKET SIZE, BY COAGULATION FACTORS, 2018-2030 (USD MILLION)
TABLE 221. ISRAEL BLOOD PLASMA DERIVATIVES MARKET SIZE, BY IMMUNOGLOBULINS, 2018-2030 (USD MILLION)
TABLE 222. ISRAEL BLOOD PLASMA DERIVATIVES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 223. ISRAEL BLOOD PLASMA DERIVATIVES MARKET SIZE, BY THERAPEUTIC USE, 2018-2030 (USD MILLION)
TABLE 224. ISRAEL BLOOD PLASMA DERIVATIVES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 225. ISRAEL BLOOD PLASMA DERIVATIVES MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
TABLE 226. ITALY BLOOD PLASMA DERIVATIVES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 227. ITALY BLOOD PLASMA DERIVATIVES MARKET SIZE, BY COAGULATION FACTORS, 2018-2030 (USD MILLION)
TABLE 228. ITALY BLOOD PLASMA DERIVATIVES MARKET SIZE, BY IMMUNOGLOBULINS, 2018-2030 (USD MILLION)
TABLE 229. ITALY BLOOD PLASMA DERIVATIVES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 230. ITALY BLOOD PLASMA DERIVATIVES MARKET SIZE, BY THERAPEUTIC USE, 2018-2030 (USD MILLION)
TABLE 231. ITALY BLOOD PLASMA DERIVATIVES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 232. ITALY BLOOD PLASMA DERIVATIVES MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
TABLE 233. NETHERLANDS BLOOD PLASMA DERIVATIVES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 234. NETHERLANDS BLOOD PLASMA DERIVATIVES MARKET SIZE, BY COAGULATION FACTORS, 2018-2030 (USD MILLION)
TABLE 235. NETHERLANDS BLOOD PLASMA DERIVATIVES MARKET SIZE, BY IMMUNOGLOBULINS, 2018-2030 (USD MILLION)
TABLE 236. NETHERLANDS BLOOD PLASMA DERIVATIVES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 237. NETHERLANDS BLOOD PLASMA DERIVATIVES MARKET SIZE, BY THERAPEUTIC USE, 2018-2030 (USD MILLION)
TABLE 238. NETHERLANDS BLOOD PLASMA DERIVATIVES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 239. NETHERLANDS BLOOD PLASMA DERIVATIVES MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
TABLE 240. NIGERIA BLOOD PLASMA DERIVATIVES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 241. NIGERIA BLOOD PLASMA DERIVATIVES MARKET SIZE, BY COAGULATION FACTORS, 2018-2030 (USD MILLION)
TABLE 242. NIGERIA BLOOD PLASMA DERIVATIVES MARKET SIZE, BY IMMUNOGLOBULINS, 2018-2030 (USD MILLION)
TABLE 243. NIGERIA BLOOD PLASMA DERIVATIVES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 244. NIGERIA BLOOD PLASMA DERIVATIVES MARKET SIZE, BY THERAPEUTIC USE, 2018-2030 (USD MILLION)
TABLE 245. NIGERIA BLOOD PLASMA DERIVATIVES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 246. NIGERIA BLOOD PLASMA DERIVATIVES MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
TABLE 247. NORWAY BLOOD PLASMA DERIVATIVES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 248. NORWAY BLOOD PLASMA DERIVATIVES MARKET SIZE, BY COAGULATION FACTORS, 2018-2030 (USD MILLION)
TABLE 249. NORWAY BLOOD PLASMA DERIVATIVES MARKET SIZE, BY IMMUNOGLOBULINS, 2018-2030 (USD MILLION)
TABLE 250. NORWAY BLOOD PLASMA DERIVATIVES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 251. NORWAY BLOOD PLASMA DERIVATIVES MARKET SIZE, BY THERAPEUTIC USE, 2018-2030 (USD MILLION)
TABLE 252. NORWAY BLOOD PLASMA DERIVATIVES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 253. NORWAY BLOOD PLASMA DERIVATIVES MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
TABLE 254. POLAND BLOOD PLASMA DERIVATIVES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 255. POLAND BLOOD PLASMA DERIVATIVES MARKET SIZE, BY COAGULATION FACTORS, 2018-2030 (USD MILLION)
TABLE 256. POLAND BLOOD PLASMA DERIVATIVES MARKET SIZE, BY IMMUNOGLOBULINS, 2018-2030 (USD MILLION)
TABLE 257. POLAND BLOOD PLASMA DERIVATIVES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 258. POLAND BLOOD PLASMA DERIVATIVES MARKET SIZE, BY THERAPEUTIC USE, 2018-2030 (USD MILLION)
TABLE 259. POLAND BLOOD PLASMA DERIVATIVES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 260. POLAND BLOOD PLASMA DERIVATIVES MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
TABLE 261. QATAR BLOOD PLASMA DERIVATIVES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 262. QATAR BLOOD PLASMA DERIVATIVES MARKET SIZE, BY COAGULATION FACTORS, 2018-2030 (USD MILLION)
TABLE 263. QATAR BLOOD PLASMA DERIVATIVES MARKET SIZE, BY IMMUNOGLOBULINS, 2018-2030 (USD MILLION)
TABLE 264. QATAR BLOOD PLASMA DERIVATIVES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 265. QATAR BLOOD PLASMA DERIVATIVES MARKET SIZE, BY THERAPEUTIC USE, 2018-2030 (USD MILLION)
TABLE 266. QATAR BLOOD PLASMA DERIVATIVES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 267. QATAR BLOOD PLASMA DERIVATIVES MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
TABLE 268. RUSSIA BLOOD PLASMA DERIVATIVES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 269. RUSSIA BLOOD PLASMA DERIVATIVES MARKET SIZE, BY COAGULATION FACTORS, 2018-2030 (USD MILLION)
TABLE 270. RUSSIA BLOOD PLASMA DERIVATIVES MARKET SIZE, BY IMMUNOGLOBULINS, 2018-2030 (USD MILLION)
TABLE 271. RUSSIA BLOOD PLASMA DERIVATIVES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 272. RUSSIA BLOOD PLASMA DERIVATIVES MARKET SIZE, BY THERAPEUTIC USE, 2018-2030 (USD MILLION)
TABLE 273. RUSSIA BLOOD PLASMA DERIVATIVES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 274. RUSSIA BLOOD PLASMA DERIVATIVES MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
TABLE 275. SAUDI ARABIA BLOOD PLASMA DERIVATIVES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 276. SAUDI ARABIA BLOOD PLASMA DERIVATIVES MARKET SIZE, BY COAGULATION FACTORS, 2018-2030 (USD MILLION)
TABLE 277. SAUDI ARABIA BLOOD PLASMA DERIVATIVES MARKET SIZE, BY IMMUNOGLOBULINS, 2018-2030 (USD MILLION)
TABLE 278. SAUDI ARABIA BLOOD PLASMA DERIVATIVES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 279. SAUDI ARABIA BLOOD PLASMA DERIVATIVES MARKET SIZE, BY THERAPEUTIC USE, 2018-2030 (USD MILLION)
TABLE 280. SAUDI ARABIA BLOOD PLASMA DERIVATIVES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 281. SAUDI ARABIA BLOOD PLASMA DERIVATIVES MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
TABLE 282. SOUTH AFRICA BLOOD PLASMA DERIVATIVES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 283. SOUTH AFRICA BLOOD PLASMA DERIVATIVES MARKET SIZE, BY COAGULATION FACTORS, 2018-2030 (USD MILLION)
TABLE 284. SOUTH AFRICA BLOOD PLASMA DERIVATIVES MARKET SIZE, BY IMMUNOGLOBULINS, 2018-2030 (USD MILLION)
TABLE 285. SOUTH AFRICA BLOOD PLASMA DERIVATIVES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 286. SOUTH AFRICA BLOOD PLASMA DERIVATIVES MARKET SIZE, BY THERAPEUTIC USE, 2018-2030 (USD MILLION)
TABLE 287. SOUTH AFRICA BLOOD PLASMA DERIVATIVES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 288. SOUTH AFRICA BLOOD PLASMA DERIVATIVES MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
TABLE 289. SPAIN BLOOD PLASMA DERIVATIVES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 290. SPAIN BLOOD PLASMA DERIVATIVES MARKET SIZE, BY COAGULATION FACTORS, 2018-2030 (USD MILLION)
TABLE 291. SPAIN BLOOD PLASMA DERIVATIVES MARKET SIZE, BY IMMUNOGLOBULINS, 2018-2030 (USD MILLION)
TABLE 292. SPAIN BLOOD PLASMA DERIVATIVES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 293. SPAIN BLOOD PLASMA DERIVATIVES MARKET SIZE, BY THERAPEUTIC USE, 2018-2030 (USD MILLION)
TABLE 294. SPAIN BLOOD PLASMA DERIVATIVES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 295. SPAIN BLOOD PLASMA DERIVATIVES MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
TABLE 296. SWEDEN BLOOD PLASMA DERIVATIVES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 297. SWEDEN BLOOD PLASMA DERIVATIVES MARKET SIZE, BY COAGULATION FACTORS, 2018-2030 (USD MILLION)
TABLE 298. SWEDEN BLOOD PLASMA DERIVATIVES MARKET SIZE, BY IMMUNOGLOBULINS, 2018-2030 (USD MILLION)
TABLE 299. SWEDEN BLOOD PLASMA DERIVATIVES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 300. SWEDEN BLOOD PLASMA DERIVATIVES MARKET SIZE, BY THERAPEUTIC USE, 2018-2030 (USD MILLION)
TABLE 301. SWEDEN BLOOD PLASMA DERIVATIVES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 302. SWEDEN BLOOD PLASMA DERIVATIVES MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
TABLE 303. SWITZERLAND BLOOD PLASMA DERIVATIVES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 304. SWITZERLAND BLOOD PLASMA DERIVATIVES MARKET SIZE, BY COAGULATION FACTORS, 2018-2030 (USD MILLION)
TABLE 305. SWITZERLAND BLOOD PLASMA DERIVATIVES MARKET SIZE, BY IMMUNOGLOBULINS, 2018-2030 (USD MILLION)
TABLE 306. SWITZERLAND BLOOD PLASMA DERIVATIVES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 307. SWITZERLAND BLOOD PLASMA DERIVATIVES MARKET SIZE, BY THERAPEUTIC USE, 2018-2030 (USD MILLION)
TABLE 308. SWITZERLAND BLOOD PLASMA DERIVATIVES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 309. SWITZERLAND BLOOD PLASMA DERIVATIVES MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
TABLE 310. TURKEY BLOOD PLASMA DERIVATIVES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 311. TURKEY BLOOD PLASMA DERIVATIVES MARKET SIZE, BY COAGULATION FACTORS, 2018-2030 (USD MILLION)
TABLE 312. TURKEY BLOOD PLASMA DERIVATIVES MARKET SIZE, BY IMMUNOGLOBULINS, 2018-2030 (USD MILLION)
TABLE 313. TURKEY BLOOD PLASMA DERIVATIVES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 314. TURKEY BLOOD PLASMA DERIVATIVES MARKET SIZE, BY THERAPEUTIC USE, 2018-2030 (USD MILLION)
TABLE 315. TURKEY BLOOD PLASMA DERIVATIVES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 316. TURKEY BLOOD PLASMA DERIVATIVES MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
TABLE 317. UNITED ARAB EMIRATES BLOOD PLASMA DERIVATIVES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 318. UNITED ARAB EMIRATES BLOOD PLASMA DERIVATIVES MARKET SIZE, BY COAGULATION FACTORS, 2018-2030 (USD MILLION)
TABLE 319. UNITED ARAB EMIRATES BLOOD PLASMA DERIVATIVES MARKET SIZE, BY IMMUNOGLOBULINS, 2018-2030 (USD MILLION)
TABLE 320. UNITED ARAB EMIRATES BLOOD PLASMA DERIVATIVES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 321. UNITED ARAB EMIRATES BLOOD PLASMA DERIVATIVES MARKET SIZE, BY THERAPEUTIC USE, 2018-2030 (USD MILLION)
TABLE 322. UNITED ARAB EMIRATES BLOOD PLASMA DERIVATIVES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 323. UNITED ARAB EMIRATES BLOOD PLASMA DERIVATIVES MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
TABLE 324. UNITED KINGDOM BLOOD PLASMA DERIVATIVES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 325. UNITED KINGDOM BLOOD PLASMA DERIVATIVES MARKET SIZE, BY COAGULATION FACTORS, 2018-2030 (USD MILLION)
TABLE 326. UNITED KINGDOM BLOOD PLASMA DERIVATIVES MARKET SIZE, BY IMMUNOGLOBULINS, 2018-2030 (USD MILLION)
TABLE 327. UNITED KINGDOM BLOOD PLASMA DERIVATIVES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 328. UNITED KINGDOM BLOOD PLASMA DERIVATIVES MARKET SIZE, BY THERAPEUTIC USE, 2018-2030 (USD MILLION)
TABLE 3

Companies Mentioned

The leading players in the Blood Plasma Derivatives market, which are profiled in this report, include:
  • ADMA Biologics
  • ARTHREX GmbH
  • Bio Products Laboratory Ltd
  • Biotest AG
  • BPL Holdings
  • China Biologic Products Holdings, Inc.
  • CSL Behring
  • Emergent BioSolutions
  • Grifols
  • Intas Pharmaceuticals
  • Kamada Ltd.
  • Kedrion Biopharma
  • LFB Group
  • Octapharma
  • Prothya Biosolutions
  • RAAS Blood Products
  • Sanquin
  • Shanghai RAAS Blood Products Co., Ltd.
  • Sichuan Yuanda Shuyang Pharmaceutical Co., Ltd.
  • Takeda Pharmaceutical Company Limited

Methodology

Loading
LOADING...

Table Information

Report AttributeDetails
No. of Pages181
PublishedOctober 2024
Forecast Period2024 - 2030
Estimated Market Value ( USD ) in 2024 $ 523.83 Million
Forecasted Market Value ( USD ) by 2030 $ 921.33 Million
Compound Annual Growth Rate9.6%
Regions CoveredGlobal
No. of Companies Mentioned20

Related Topics

Related Reports

Blood Plasma Derivatives Market Report by Type, Application, End User, and Region 2024-2032 - Product Image

Blood Plasma Derivatives Market Report by Type, Application, End User, and Region 2024-2032

  • Report
  • 145 Pages
  • Global
From
Blood Plasma Derivatives Global Market Report 2024 - Product Image

Blood Plasma Derivatives Global Market Report 2024

  • Report
  • 175 Pages
  • Global
From
Blood Plasma Derivatives Global Market Opportunities and Strategies to 2033 - Product Image

Blood Plasma Derivatives Global Market Opportunities and Strategies to 2033

  • Report
  • 327 Pages
  • Global
From
Bovine Blood Plasma Derivatives - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2024 - 2029) - Product Image

Bovine Blood Plasma Derivatives - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2024 - 2029)

  • Report
  • 120 Pages
  • Global
From
Blood Plasma Derivatives Global Market Insights 2024, Analysis and Forecast to 2029, by Manufacturers, Regions, Technology, Application, Product Type - Product Image

Blood Plasma Derivatives Global Market Insights 2024, Analysis and Forecast to 2029, by Manufacturers, Regions, Technology, Application, Product Type

  • Report
  • 93 Pages
  • Global
From

About the Plasma Derivative Market

The Plasma Derivative market is a subset of the Blood Banking industry, which involves the collection, processing, and distribution of human blood and its components. Plasma derivatives are products derived from human plasma, such as albumin, immunoglobulins, and clotting factors. These products are used to treat a variety of medical conditions, including hemophilia, immune deficiencies, and shock. Plasma derivatives are typically collected from healthy donors and processed in a laboratory setting. The process involves separating the plasma from the other components of the blood, such as red and white blood cells. The plasma is then further processed to create the desired product. The Plasma Derivative market is highly regulated, with stringent safety and quality standards in place to ensure the safety of the products. Companies in the market include CSL Behring, Grifols, Octapharma, Kedrion, and Biotest. Show Less Read more

Copyright © 2002-2024 Research and Markets. All Rights Reserved.